Tiziana Life Sciences Plc
(NASDAQ : TLSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 0.97%349.970.0%$7054.31m
BNTXBioNTech SE -0.36%339.000.0%$1237.43m
SNSSSunesis Pharmaceuticals, Inc. -1.94%10.620.7%$742.38m
NVAXNovavax, Inc. -0.57%181.6879.8%$649.86m
AMGNAmgen, Inc. 0.41%240.781.3%$497.06m
BIIBBiogen, Inc. -1.31%327.361.7%$439.80m
VRTXVertex Pharmaceuticals, Inc. 1.00%200.301.9%$421.63m
GILDGilead Sciences, Inc. -0.09%68.291.0%$403.77m
REGNRegeneron Pharmaceuticals, Inc. -0.74%572.842.7%$313.70m
ILMNIllumina, Inc. 0.15%493.733.5%$256.69m
NTLAIntellia Therapeutics, Inc. -1.36%134.712.3%$191.67m
CRSPCRISPR Therapeutics AG -0.29%121.980.6%$137.92m
SGENSeagen Inc. 0.18%154.525.8%$128.78m
EXASEXACT Sciences Corp. -3.27%104.8618.1%$121.81m
BGNEBeiGene Ltd. -1.21%323.461.4%$120.49m

Company Profile

Tiziana Life Sciences Plc engages in the research and development of biotechnological and pharmaceutical products. It develops transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer related to the liver. Its clinical pipeline includes Foralumab, Anti IL-6R, and Milciclib. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.